Application of Corilagin in preparing anti-tumor drugs

An anti-tumor drug, anti-tumor technology, applied in anti-tumor drugs, drug combinations, pharmaceutical formulations, etc., can solve problems such as unseen pharmacology and molecular mechanisms

Active Publication Date: 2010-11-10
XIAMEN TASMAN BIO TECH
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are only 7 published patents in China (CN101461816A, CN1709901A, CN1695647A, CN1695627A, CN1197641A, CN101461831A, CN101613382A) related to the preparation of cor...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Corilagin in preparing anti-tumor drugs
  • Application of Corilagin in preparing anti-tumor drugs
  • Application of Corilagin in preparing anti-tumor drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Inhibitory effect of Corilagin on liver cancer cells, ovarian cancer cells and normal cells in vitro

[0022] Experimental materials: cell lines, culture medium, drugs: human liver cancer cell Bel7402, SMMC7721, human ovarian cancer cell Hey, human normal liver cell Chang-liver and human normal ovarian epithelial cell NOE001 were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences; Base RPMI 1640 was purchased from GIBCO Company, fetal bovine serum was purchased from Hyclone Company, penicillin and streptomycin were purchased from Shanghai Sangong Company; 3-(4,5-dimethylthiazole-2)-2,5-diphenyl Tetrazolium bromide (abbreviated as MTT), dimethyl sulfoxide (abbreviated as DMSO) and the like were purchased from Sigma or other domestic companies.

[0023] Experimental method: A group of corilagin at concentrations of 0, 6.25, 12.5, 25, 50, 100, and 200 μg / mL was applied to cells Bel7402, SMMC7721, Hey, Chang-liver, and NOE00172 h, and t...

Embodiment 2

[0025] Example 2 Currylatin's arresting effect on the cell cycle of ovarian cancer cell Hey

[0026] Hey cells were inoculated in 60mm culture dishes, and co-cultured with 17 μg / ml corilagin for 24h, 48h, and 72h (the method was the same as in Example 1), and a control was made. After being treated with 5 mg / ml PI containing 0.1% RNaseA in the dark for 10 min, it was detected by flow cytometry.

[0027]The results showed that from 24h to 72h, the G0 / G1 phase of the control group decreased from 48.88% to 39.29%, while that of the Corilagin group increased from 54.85% to 71.75% ( figure 2 ). It can be seen that Corilagin can arrest the cell cycle of ovarian cancer cell Hey in the G0 / G1 phase in a time-effect-dependent manner. See Table 1 for the cell cycle arrest effect of Corilagin on ovarian cancer cell Hey.

[0028] Table 1

[0029]

Embodiment 3

[0030] Example 3 Effect of Corilagin on TGF-β / PI3K / Akt / Snail Signaling Pathway in SKOV3ip Cells

[0031] Cell inoculation: Mix human ovarian cancer cell SKOV3ip in 10% FBS RPMI 1640 and inoculate in 60mm culture dish, the number of cells in each dish is 3.5×10 5 indivual. Drug addition: Add 32 μg / ml drug A and 17 μg / ml drug C to the cells in sequence.

[0032] After 12 hours: starvation: replace the culture medium with RPMI 1640 without FBS, and the drug concentration is the same as before.

[0033] After 36 hours: Add epidermal growth factor EGF (concentration: 20 μg / ml) to one of the two dishes of cells in each group, and act for 10 minutes to extract protein.

[0034] Western blot detection of pAkt and Akt: Bradford protein quantification method was used to make the total amount of protein per well 20 μg, and pAkt (p473) and Akt antibodies were used to detect (CST Company, rabbit anti-antibody, antibody concentration 1:1000).

[0035] The results show that Corilagin can ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a Corilagin compound, in particular to the application of Corilagin in preparing anti-tumor drugs. The chemical name of Corilagin is 1-O-trigalloyl-3,6-O-hexahydroxydiphenoyl-beta-D-glucose, and the molecular formula thereof is C27H22O18. The anti-tumor drug for oral administration or injection comprises a drug resisting the tumor growth or a drug resisting tumor invasionand metastasis, wherein the injection can be intravenous injection, intramuscular injection, intraperitoneal injection or subcutaneous injection. According to the tests, the Corilagin achieves good anti-tumor effect, more particularly, the Corilagin achieves good curative effect in both in-vitro tumor cell tests and in-vivo tumor animal models. Therefore, the Corilagin as a novel compound achieving the anti-tumor effect is applicable in preparing anti-tumor drugs.

Description

technical field [0001] The present invention relates to a compound corilagin, in particular to the application of corilagin in the preparation of antitumor drugs. Background technique [0002] Tumor is a common and frequently-occurring disease, among which malignant tumor (cancer) is the most serious disease that endangers human health. According to the data released by the Ministry of Health of my country, the death rate of malignant tumors in both rural and urban populations in China ranked first in 2006. And the danger of malignant tumor is still increasing day by day. Currently, the top 10 common malignant tumors in my country are lung cancer, gastric cancer, esophageal cancer, colon cancer, liver cancer, cervical cancer, breast cancer, leukemia, malignant lymphoma, and nasopharyngeal cancer. Among many malignant tumors, liver cancer and ovarian cancer are the most difficult to treat. The mortality rate of patients remains high all year round, and the 5-year survival r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7024A61P35/00A61P35/04
Inventor 明艳林郁茵华陈良华金鸿雁郑志忠童庆宣郑国华吴美爱
Owner XIAMEN TASMAN BIO TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap